A5049813454- Dementia and Cognitive Impairment Research
- Neurological Disease Mechanisms and Treatments
- Neurological Disorders and Treatments
- MicroRNA in disease regulation
Shanghai Mental Health Center
2020-2025
Shanghai Jiao Tong University
2025
Ruijin Hospital
2025
As the population in China rapidly ages, prevalence of mild cognitive impairment (MCI) is increasing considerably. However, causes MCI vary. The continued lack understanding various subtypes impedes implementation effective measures to reduce risk advancing more severe diseases. To estimate and incidence rates two subtypes-amnestic (aMCI) vascular without dementia (VCIND)-and determine modifiable factors for them among older individuals a multiregional Chinese cohort. This 1-year...
Abstract Background: Sodium oligomannate (GV-971), a marine-derived oligosaccharide, is novel agent that may improve cognition in AD patients. Methods: The 24-week multi-center, randomized, double-blind, placebo parallel controlled clinical trial was conducted China between 24 October 2011 and 10 July 2013. study included 4-week screening/washout period, followed by treatment period. Patients were randomized 1:1:1 ratio to receive GV-971 900 mg, 600 or capsule respectively. primary outcome...
Abstract Background: Amnestic mild cognitive impairment (aMCI) is a prodromal stage of Alzheimer’s disease with the beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) imbalance. Altered microRNAs (miRNA) associated BACE1 may be potential biomarkers for aMCI diagnosis. The aims this study were to find an effective diagnostic model aMCI, and explore modulation candidate miRNAs on expression. Methods: Plasma RNA was extracted from participants enrolled in China longitudinal aging...